南方财经10月9日电，深科达（688328.SH）公告，其募投项目深科达智能制造创新示范基地续建工程 因市场环境变化及产能利用不及预期，拟调整方向，变更部分子项目并新增三个研发类项目。截至2025 年6月30日，该项目已投入募集资金14,942.38万元，剩余募集资金21,056.95万元（含利息及理财收益） 将全部用于新募投项目。具体用途为：投入9,000.00万元实施新型显示设备研发项目，7,500.00万元用于 半导体新一代测试设备研发项目，4,556.95万元投向核心零部件研发项目。此次变更主因系消费电子行 业复苏乏力、显示面板需求未显著增长，叠加公司首发募投项目产能尚未完全释放，导致原项目实施必 要性下降。同时，半导体先进封装设备研发周期长、客户认证难，而传统封装测试设备市场需求稳定且 技术路径成熟，公司据此将原半导体先进封装测试设备研发及生产项目调整为覆盖传统与先进封装的半 导体新一代测试设备研发项目。 ...

在2023年下半年被延期，今年初被降低投资额度和再次延期之后，苏州万祥科技股份有限公司（下称"万祥科技"，301180.SZ)的"新建微型锂离子电池及精 密零部件生产项目"（下称"电池项目"），仍未能迎来一个完整的结局。 9月26日，万祥科技发布公告称，公司于9月25日召开董事会、监事会等会议，审议通过了《关于终止部分募集资金投资项目并将剩余募集资金永久补充流动 资金的议案》，同意终止"电池项目"，并将剩余募集资金永久补充流动资金，本事项尚需提交公司股东会审议。 公开资料显示，万祥科技创立于2003年，总部位于江苏省苏州市，注册资本4亿元人民币。在创业初期，万祥科技以模具制造业务起家，目前已转型成为消 费电子精密零组件、新能源汽车电池零部件供应商，旗下拥有重庆井上通、东莞万仕祥、常州微宙电子、常州万祥新能源等8家全资子公司。 对此，万祥科技指出，随着公司"电池项目"的实施推进，该项目募集资金投资进度已达80%，项目已基本建设完成，已投产的生产设备已具备量产能力，且 已开始产品量产和交付。现有的产能在一定时间段内已能够满足客户开发和生产需要，考虑到外部经济环境以及自身客户需求等因素，为避免设备空置，公 司决定稳 ...

Core Viewpoint - Fujian Wancheng Biotechnology Group Co., Ltd. (Wancheng Group) has submitted its prospectus for listing on the Hong Kong Stock Exchange, aiming to expand its operations and enhance its market presence [1][9]. Group 1: Company Overview - Wancheng Group is the parent company of the snack brand "Haoxianglai" and was listed on the Shenzhen Stock Exchange in April 2021 with an IPO price of 7.19 CNY per share, raising approximately 276 million CNY [3][9]. - The company focuses on the research, cultivation, and sales of fresh edible fungi, and has recently expanded into the retail snack industry [7][9]. Group 2: Financial Performance - Wancheng Group's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately 549 million CNY, 9.29 billion CNY, 32.33 billion CNY, and 10.92 billion CNY, respectively [13][14]. - The net profit figures for the same periods were approximately 67.85 million CNY, -176.21 million CNY, 610.91 million CNY, and 136.17 million CNY [14][16]. Group 3: Investment Projects - The company initially planned to raise 600 million CNY for various projects, including a 21,000-ton mushroom production facility, but later adjusted its fundraising goals and project allocations [4][5][10]. - In September 2023, Wancheng Group announced a reduction in the investment amount for the "60-ton daily mushroom production project" from approximately 130 million CNY to 80.6 million CNY, reallocating the remaining funds to the "53,000-ton golden needle mushroom production project" [5][6]. Group 4: Shareholder Structure - As of December 31, 2022, the actual controller of Wancheng Group, Wang Zenin, held a direct stake of 5.08% and controlled a total of 51.26% of the company through various entities [7][9]. - Wang Zenin participated in a private placement of shares at a price of 11.30 CNY per share, raising 200 million CNY for brand marketing and operational support projects [10][12]. Group 5: Market Position and Future Plans - Wancheng Group's brand "Haoxianglai" is projected to rank first in China's snack and beverage retail sector by GMV in 2024, with over 15,000 stores across 29 provinces and municipalities by June 30, 2025 [12][13]. - The company has integrated its snack brands into a national brand strategy, enhancing its market presence and operational efficiency [8][9].

Core Viewpoint - Cansun Technology (688061) has announced a share buyback plan and the initiation of foreign exchange derivative trading to mitigate risks and adjust project timelines [1][2][3] Company Announcements - The company plans to repurchase shares through centralized bidding, with a minimum amount of 20 million yuan and a maximum of 40 million yuan, at a price not exceeding 52.46 yuan per share [1][3] - The company will use its own funds to engage in foreign exchange derivative trading, with a maximum contract value of 100 million yuan at any given time [2][3] - The timeline for the "High-Performance Sensor R&D and Industrialization Project" has been postponed to September 2027, and the "Special Integrated Circuit Packaging Construction Project" has been adjusted to October 2027 [2][3] Shareholder Information - As of September 15, 2025, the largest shareholder is Shanghai Jingyang Investment Consulting Co., Ltd., holding 51,988,283 shares, accounting for 45.25% [2]

Core Viewpoint - Brother Technology (002562.SZ) experienced a significant stock price increase due to strong performance forecasts for the first three quarters of 2025, with expected net profit growth of 207.32% to 253.42% year-on-year [1] Financial Performance - The company anticipates a net profit of 1 billion to 1.15 billion yuan for the first three quarters of 2025, with a non-recurring net profit forecast of 970 million to 1.12 billion yuan, reflecting year-on-year growth of 291.79% to 352.37% [1] - For Q3 2025, the expected net profit is between 354.59 million and 504.59 million yuan, indicating a year-on-year increase of 92.49% to 173.92% [1] - In the first half of 2025, Brother Technology reported revenue of 1.811 billion yuan, a 3.45% increase year-on-year, and a net profit of 645.41 million yuan, up 357.17% year-on-year [1] Business Drivers - The strong growth is attributed to rising prices of certain vitamin products, increased capacity utilization and sales of the phenol project, and a decrease in costs leading to improved overall gross margins [1] - The company’s strategic shift towards phenol production, following the termination of a natural flavor project, has allowed it to capitalize on the rising vitamin prices [2][3] Market Performance - Following the positive earnings outlook, Brother Technology's stock price reached a limit-up, closing at 7.25 yuan per share, marking a significant recovery from a low of 3.26 yuan per share in April 2025 [1][5] Shareholder Activity - Despite the positive business performance, the actual controller of Brother Technology, Qian Zhida, has been actively reducing his stake, selling approximately 26.87 million shares for about 146 million yuan between July 4 and July 15, 2025, citing personal funding needs [6]

Core Viewpoint - The company, Demingli (001309.SZ), announced adjustments to its fundraising projects to optimize internal resources and improve operational efficiency without changing the total investment amount or terminating any projects [1] Group 1: Project Adjustments - The investment amount for the "PCIe SSD storage controller chip and storage module R&D and industrialization project" will increase from 498.5614 million to 743.3595 million [1] - The investment amount for the "embedded storage controller chip and storage module R&D and industrialization project" will decrease from 666.8090 million to 340.4756 million [1] - The implementation locations for both projects will now include Guangming District, Shenzhen [1] Group 2: Project Scope - The adjustments will not affect the "information system upgrade construction project" or the "supplementary working capital project" [1]

Core Viewpoint - The company, Demingli (001309.SZ), announced adjustments to its fundraising projects to optimize internal resources and improve operational efficiency while maintaining the total investment amount and project implementation主体 [1] Investment Project Adjustments - The investment amount for the "PCIe SSD storage controller chip and storage module R&D and industrialization project" will increase from 498.5614 million to 743.3595 million [1] - The investment amount for the "embedded storage controller chip and storage module R&D and industrialization project" will decrease from 666.8090 million to 340.4756 million [1] - The implementation locations for both projects will now include Guangming District, Shenzhen [1] Project Exclusions - The adjustments do not affect the "Information System Upgrade Construction Project" and the "Supplementary Working Capital Project" [1]

德明利公告，拟调整2023年向特定对象发行股票募投项目"PCIe SSD存储控制芯片及存储模组的研发和 产业化项目"和"嵌入式存储控制芯片及存储模组的研发和产业化项目"的投资总额、内部投资结构及增 加项目实施地点。其中，"PCIe SSD存储控制芯片及存储模组的研发和产业化项目"投资总额将从4.99亿 元调整为7.43亿元，"嵌入式存储控制芯片及存储模组的研发和产业化项目"投资总额将从6.67亿元调整 为3.4亿元。此次调整旨在优化资源配置，提高经营管理效率及募集资金使用效率。 ...

Core Viewpoint - The company, Zhejiang Tianzhen Technology Co., Ltd., is undergoing significant changes in its fundraising projects and operational strategies due to external trade pressures and internal performance challenges [1][3][8]. Summary by Relevant Sections Company Operations and Fundraising Projects - The company has extended the construction period of its fundraising project in the U.S. to June 30, 2027, changing the project from an annual production capacity of 3 million square meters to 2 million square meters of new inorganic composite flooring [1][2][4]. - The U.S. project is now managed by a new entity, Boson New Materials Company, located in Georgia, with construction expected to start in December 2024 and production to begin in July 2025 [1][2][4]. Performance and Challenges - The company has faced significant challenges due to U.S. customs imposing strict import restrictions, which have severely impacted export orders and overall business performance [2][3][8]. - As of 2024, the company is projected to incur losses, prompting it to enhance research and development efforts and explore new product lines to stabilize its operations [3][8]. Compliance and Regulatory Actions - The company has been reminded to continuously monitor factors leading to performance fluctuations and to fulfill its information disclosure obligations [2][3][10]. - Due to the improper use of idle fundraising capital, the company and its executives received warnings from regulatory bodies, necessitating a comprehensive review and improvement of internal controls related to fundraising management [9][10].

Core Viewpoint - The report details the usage of previously raised funds by Fujian Wancheng Biotechnology Group Co., Ltd., highlighting the financial management and adjustments made to investment projects to enhance operational efficiency and market competitiveness [2][12][14]. Fundraising Overview - The company raised a net amount of RMB 228.60 million from its initial public offering (IPO) after deducting issuance costs [2]. - In a subsequent issuance to specific investors, the company raised RMB 200 million, with a net amount of RMB 193.60 million after expenses [3]. Fund Usage and Management - As of June 30, 2025, the company had utilized RMB 162.59 million from the IPO funds and RMB 142.49 million from the specific issuance funds [4][5]. - The company established special accounts for managing the raised funds, ensuring compliance with regulatory requirements and protecting investor interests [9][10]. Project Adjustments - The company changed the investment project from "Annual Production of 21,000 Tons of Shimeji Mushroom" to "Annual Production of 53,000 Tons of Enoki Mushroom," aiming to improve market competitiveness and reduce production costs [12][14]. - The adjusted investment amount for the new project is RMB 100 million, with a total planned investment of RMB 470.57 million [14]. Financial Performance - As of June 30, 2025, the project for producing 53,000 tons of Enoki mushrooms reported a cumulative loss of RMB 51.39 million, indicating challenges in the edible mushroom business due to market conditions [16].